Exceptional response to Everolimus in a pancreatic NET G3 (pNET) – How NGS can help in treatment choice

#3891

Introduction: Exceptional Responders are defined as patients who achieve complete (CR) or partial response (PR) for at least 6 months to a treatment with population PR or CR rate less than 10%, or patients with CR or PR lasting more than three times the median duration of response.

Aim(s): We present a case of a 66-year-old female patient affected by well-differentiated pNET metastatic at diagnosis (G1, Ki-67 2% on pancreas biopsy).

Materials and methods: We collected clinical and molecular data. NGS was performed by in-house and FoundationONE® CDx assays.

Conference:

Presenting Author: Torresan I

Authors: Torresan I, Mafficini A, Benini L, Borghesani M, Moscarda V,

Keywords: pNET, NGS, G3, everolimus, TSC2,